Amicus Therapeutics is a biopharmaceutical company that is dedicated to the development of pharmacological chaperones--small-molecule drugs that are given to patients orally. The developed drugs are designed to treat a variety of diseases, including neurodegeneration diseases and lysosomal storage disorders. The company was founded by a Princeton native with the goal to develop new techniques to help and save his sick children.